{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-061773","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2026-05-15T11:07:13+00:00","discovered_at":"2026-05-15T11:10:00.311202+00:00","generated_at":"2026-05-15T11:10:12.221118+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioXcel reports Q1 net loss $12.7M; FDA sets Nov 14 PDUFA for at-home IGALMI","bullets":["FDA accepted sNDA for IGALMI at-home use in agitation associated with bipolar/schizophrenia; PDUFA date Nov 14, 2026.","Net revenue $206K (up 23% YoY from $168K); net loss $12.7M vs $7.3M in Q1 2025.","Engaged MTS Health Partners to explore strategic options including sale, merger, or collaboration.","Cash and equivalents $17.2M as of Mar 31, 2026; company in compliance with credit covenants.","R&D down to $3.0M from $4.6M due to SERENITY trial completion; SG&A up to $7.2M from $5.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-061773","json":"https://secwatch.observer/filing/0001104659-26-061773.json","markdown":"https://secwatch.observer/filing/0001104659-26-061773.md","text":"https://secwatch.observer/filing/0001104659-26-061773.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/0001104659-26-061773-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/tm2614679d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:10:12.221118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d7994f1a800c7d817bf6d2088057f15c777be97","claim":"BioXcel Therapeutics, Inc. reported the three months ended March 31, 2026 results: revenue $206,000, net income net loss of $12.7 million.","evidence_excerpt":"FDA approval in an adjacent indication, which is further reinforcing the need in this therapeutic area. First Quarter 2026 Financial Results Net revenue from IGALMI® was $206,000 for the first quarter of 2026, compared to $168,000 for the same period in 2025. The Company is focused on preparing for IGALMI’s launch in the at-home setting and maintaining","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720893/000110465926061773/0001104659-26-061773-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Revenue","value":"$206,000"},{"label":"Net income","value":"net loss of $12.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}